{"abstract":"The National Human Genome Research Institute (NHGRI), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive commercialization patent license to practice the inventions embodied in the Patent Applications listed in the Supplementary Information section of this notice License to Selecta Biosciences (\"Selecta\") located in Watertown, Massachusetts.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2017/01/03/2016-31834.html","cfr_references":[],"citation":"82 FR 132","comment_url":null,"comments_close_on":"2017-01-18","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before January 18, 2017 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2016-31834","effective_on":null,"end_page":133,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2017/01/03/2016-31834.xml","html_url":"https://www.federalregister.gov/documents/2017/01/03/2016-31834/prospective-grant-of-exclusive-license-development-manufacture-and-commercialization-of-gene-therapy","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2016-31834?publication_date=2017-01-03","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2017-01-03/2016-31834/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":100,"last_updated":"2026-06-25 12:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2017-01-03/pdf/2016-31834.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2016-31834.pdf?1483105563","publication_date":"2017-01-03","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2017/01/03/2016-31834.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T00:26:34Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":132,"subtype":null,"title":"Prospective Grant of Exclusive License: Development, Manufacture and Commercialization of Gene Therapy Products for Human Gene Therapy Use To Treat and/or Prevent Methylmalonic Acidemia (MMA)","toc_doc":"Development, Manufacture and Commercialization of Gene Therapy Products for Human Gene Therapy Use to Treat and/or Prevent Methylmalonic Acidemia","toc_subject":"Prospective Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":82}